Clinical trials: Pseudomonas Infections
Non-Cystic Fibrosis Bronchiectasis
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.
- Trial name
- NOPA (NCT06663176)
- Testing
- RESP302, RESP303
- Where
- Ukraine
- Volunteers
- 60 people
- Sponsor
- Thirty Respiratory Limited
Pseudomonas
Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia
Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of "standard dose" or "high dose" sensitivity.
- Trial name
- Mero-Pyo (NCT06113107)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Cystic Fibrosis
Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
This is a study to examine the safety, effect on lung function, and frequency of symptoms relating to cystic fibrosis during 24 weeks of treatment with the antibiotic azithromycin in 6-18 year-olds with CF who are not infected…
- Trial name
- NCT00431964
- Testing
- azithromycin 250 mg tablets
- Where
- 40 sites in United States, Canada
- Volunteers
- 263 people
- Sponsor
- CF Therapeutics Development Network Coordinating Center
Cystic Fibrosis
Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of…
- Trial name
- NCT01044719
- Testing
- Ceftazidime, Tobramycin, Meropenem
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- Imperial College London
Cystic Fibrosis, Pseudomonas Aeruginosa
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients…
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pulmonary Exacerbation
- Trial name
- NCT00333385
- Testing
- ceftazidime
- Where
- 15 sites in France
- Volunteers
- 120 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Bronchiectasis Adult, Pseudomonas Aeruginosa Infection
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity.
- Trial name
- ERASE (NCT06093191)
- Testing
- Tobramycin Inhalant Product, Ciprofloxacin 750 MG, Natural saline inhalation
- Where
- 60 sites in China
- Volunteers
- 371 people
- Sponsor
- Jin-Fu Xu
Surgical Site Infection, Staphylococcus Aureus Infection
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S.
- Conditions
- Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection, Bacterial Infections
- Trial name
- NCT06319235
- Testing
- IMP
- Where
- Czechia
- Volunteers
- 52 people
- Sponsor
- MB PHARMA s.r.o.
Pseudomonas Aeruginosa Infection
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa
The main objective is to verify that the administration of piperacillin / tazobactam administered by continuous infusion to treat complicated infections or with known or suspected nosocomial isolation of Pseudomonas aeruginosa is…
- Trial name
- PiperTazo (NCT01577368)
- Testing
- Piperacillin-Tazobactam continuous infusion, Piperacillin-Tazobactam intermittent infusion
- Where
- Spain
- Volunteers
- 76 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Cystic Fibrosis
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution.
- Trial name
- ELITE (NCT00391976)
- Testing
- Tobramycin solution for inhalation 300 mg
- Volunteers
- 123 people
- Sponsor
- Novartis
Osteomyelitis, Pseudomonas Infections
Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa
This study looks at how well one antibiotic (monotherapy) works compared to two antibiotics (combination therapy) in treating bone infections caused by Pseudomonas aeruginosa.
- Conditions
- Osteomyelitis, Pseudomonas Infections, Pseudomonas Aeruginosa, Bacterial Infections
- Trial name
- NCT07056881
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB)…
- Trial name
- NCT07709494
- Testing
- Rev-56 for Inhalation
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Revagenix, Inc.
COPD, Respiratory Tract Infections
Targeted AntiBiotics for Chronic Pulmonary Diseases
This is a prospective, randomized multi-center trial investigating the impact of lower airway infection with P. aeruginosa in COPD patients. The aim of the study is to evaluate if targeted antibiotic therapy against P.
- Conditions
- COPD, Respiratory Tract Infections, Pseudomonas Aeruginosa, Bronchiectasis
- Trial name
- Target-ABC (NCT03262142)
- Testing
- Piperacillin/tazobactam, Ciprofloxacin
- Where
- Denmark
- Volunteers
- 51 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Brain and Central Nervous System Tumors
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells.
- Trial name
- NCT00074334
- Testing
- TGFa-PE38 immunotoxin, conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pediatric Brain Tumor Consortium
Cystic Fibrosis, Pseudomonas Aeruginosa
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P.
- Trial name
- EAP (NCT00989807)
- Testing
- Aztreonam lysine
- Where
- 4 sites in Canada
- Sponsor
- Gilead Sciences
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
BRONCHIECTASIS
Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa
Statins are a class of drug used to prevent heart attacks and strokes by lowering blood cholesterol levels. They have also been found to have a beneficial "side effect" of lowering the level of inflammation in the body.
- Trial name
- NCT01299194
- Testing
- ATORVASTATIN
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University of Edinburgh
MDRPA
Clinical Study on the Treatment of Lower Respiratory Tract Infection With Pseudomonas Aeruginosa by Ceftazidime and Avibatam
Multidrug-resistant Gram-negative bacteria (MDR-GNB) is emerging globally as a pathogen of concern in healthcare-associated infections (HAIs), and a threat to public health.There has been an alarming rise in the prevalence of…
- Trial name
- NCT06992102
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Brain and Central Nervous System Tumors
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma.
- Trial name
- NCT00003842
- Testing
- interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barrett Cancer Center
Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
This is a Phase I/IIa trial designed to evaluate topical bacteriophage therapy in patients with diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection, Staphylococcus Aureus Infection, Acinetobacter Infection
- Trial name
- REVERSE (NCT04803708)
- Testing
- TP-102
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Technophage, SA
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University